Fate Therapeutics, Inc. (FATE) Forms $11.34 Double Top; Oracle Investment Management Lifted By $568,361 Its Epizyme (EPZM) Position

July 1, 2018 - By Annabelle Johnson

Epizyme, Inc. (NASDAQ:EPZM) Logo

Oracle Investment Management Inc increased Epizyme Inc (EPZM) stake by 9.21% reported in 2018Q1 SEC filing. Oracle Investment Management Inc acquired 33,433 shares as Epizyme Inc (EPZM)’s stock rose 3.36%. The Oracle Investment Management Inc holds 396,325 shares with $7.04 million value, up from 362,892 last quarter. Epizyme Inc now has $941.56M valuation. The stock increased 2.26% or $0.3 during the last trading session, reaching $13.55. About 356,438 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since July 1, 2017 and is uptrending. It has outperformed by 1.67% the S&P500. Some Historical EPZM News: 13/03/2018 – EPIZYME INC EPZM.O : LEERINK RAISES TARGET PRICE TO $24 FROM $22; RATING OUTPERFORM; 23/04/2018 – EPIZYME: FDA ISSUED PARTIAL CLINICAL HOLD ON TAZEMETOSTAT TRIAL; 12/03/2018 – Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors; 13/03/2018 – Epizyme 4Q Loss/Shr 52c; 13/03/2018 – EPIZYME 4Q LOSS/SHR 52C, EST. LOSS/SHR 57C; 20/04/2018 – DJ Epizyme Inc, Inst Holders, 1Q 2018 (EPZM); 08/05/2018 – Epizyme at American Society of Clinical Oncology Meeting Jun 1; 23/04/2018 – FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case $EPZM; 09/04/2018 – EPIZYME’S TAZEMETOSTAT ESTABLISHED RECOMMENDED DOSE FOR PHASE 2; 23/04/2018 – EPIZYME -U.S. FDA ISSUED PARTIAL CLINICAL HOLD AFFECTING NEW ENROLLMENT OF PATIENTS WITH GENETICALLY DEFINED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES

Fate Therapeutics, Inc. (FATE) formed double top with $12.02 target or 6.00% above today’s $11.34 share price. Fate Therapeutics, Inc. (FATE) has $599.41M valuation. The stock increased 1.61% or $0.18 during the last trading session, reaching $11.34. About 676,863 shares traded or 3.98% up from the average. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 233.04% since July 1, 2017 and is uptrending. It has outperformed by 220.47% the S&P500. Some Historical FATE News: 16/05/2018 – FATE THERAPEUTICS, MEMORIAL SLOAN KETTERING EXPAND LICENSE PACT; 06/03/2018 – FATE THERAPEUTICS INC FATE.O : LEERINK RAISES TARGET PRICE TO $16 FROM $11; 19/03/2018 – FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™; 29/03/2018 – Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the lnnate Killer Summit 2018; 10/05/2018 – Invus Public Equities Advisors Buys 1.6% of Fate Therapeutics; 05/03/2018 – Fate Therapeutics 4Q Rev $1.03M; 04/05/2018 – FATE THERAPEUTICS FILES $150M MIXED SECURITIES SHELF; 23/04/2018 – DJ Fate Therapeutics Inc, Inst Holders, 1Q 2018 (FATE); 16/05/2018 – Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to Include Gene-edited T-cell Immunotherapies; 05/03/2018 – FATE THERAPEUTICS SEES FT500 IND FILING IN FIRST HALF 2018

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on August, 13. They expect $-0.26 EPS, down 13.04% or $0.03 from last year’s $-0.23 per share. After $-0.27 actual EPS reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.70% EPS growth.

Among 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Fate Therapeutics has $20 highest and $1200 lowest target. $17.80’s average target is 56.97% above currents $11.34 stock price. Fate Therapeutics had 10 analyst reports since March 6, 2018 according to SRatingsIntel. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Tuesday, March 6 with “Buy” rating. The firm has “Buy” rating by Wells Fargo given on Friday, April 6. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Wednesday, May 16 with “Buy” rating. H.C. Wainwright maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Tuesday, March 20 with “Hold” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Neutral” rating given on Tuesday, March 6 by H.C. Wainwright. The firm earned “Hold” rating on Thursday, March 29 by H.C. Wainwright. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, March 6 by BMO Capital Markets. The firm earned “Hold” rating on Tuesday, March 6 by Raymond James. Wedbush maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Tuesday, March 6. Wedbush has “Outperform” rating and $19 target. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) on Thursday, March 15 with “Buy” rating.

Investors sentiment increased to 2.08 in Q1 2018. Its up 0.50, from 1.58 in 2017Q4. It improved, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 23 funds opened positions while 31 raised stakes. 36.46 million shares or 12.96% more from 32.27 million shares in 2017Q4 were reported. Tower Capital Ltd Co (Trc) owns 71 shares for 0% of their portfolio. Price T Rowe Associate Md owns 962,773 shares or 0% of their US portfolio. 36,977 were reported by Manufacturers Life Insur The. Citigroup Inc has 10,298 shares. Ameriprise Financial has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 88,364 shares. Tiaa Cref Investment Mngmt Ltd Liability reported 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Community Bancorp Na has 1,500 shares for 0% of their portfolio. State Bank Of New York Mellon holds 0% or 276,690 shares in its portfolio. Pura Vida Invests Ltd Llc owns 59,600 shares or 0% of their US portfolio. Td Asset Mngmt Inc invested in 0% or 41,600 shares. Nuveen Asset Mgmt Ltd Co has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Tci Wealth Advsr reported 0.01% stake. Deutsche State Bank Ag invested 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Panagora Asset Mgmt holds 0% or 11,239 shares. Rhumbline Advisers has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE).

Investors sentiment increased to 1.5 in 2018 Q1. Its up 0.29, from 1.21 in 2017Q4. It is positive, as 13 investors sold EPZM shares while 25 reduced holdings. 22 funds opened positions while 35 raised stakes. 57.44 million shares or 0.90% more from 56.93 million shares in 2017Q4 were reported. Metropolitan Life Insurance New York has 15,871 shares. Point72 Asia (Hong Kong) Ltd invested in 1,899 shares. Jacobs Levy Equity Management holds 46,250 shares. Deutsche Bank Ag has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Great West Life Assurance Can reported 4,800 shares or 0% of all its holdings. Tiaa Cref Invest Management Ltd Limited Liability Company has 110,943 shares for 0% of their portfolio. Royal Retail Bank Of Canada holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 880 shares. Blackrock holds 0% or 3.90 million shares. Voya Mgmt Ltd Liability Company holds 0.02% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 606,547 shares. Rock Springs Cap Management LP reported 1.28 million shares. Jgp Glob Gestao De Recursos Ltda accumulated 15,333 shares. Sio Cap Management Limited Liability Co has invested 0.78% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). 157,043 are owned by Pdts Prns Limited Liability. 49,300 were accumulated by State Of Wisconsin Invest Board. Macquarie Limited has invested 0.01% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM).

Since February 5, 2018, it had 0 insider purchases, and 1 sale for $1.20 million activity. 72,264 shares were sold by Ros Matthew, worth $1.20M.

Among 7 analysts covering Epizyme (NASDAQ:EPZM), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Epizyme had 9 analyst reports since January 10, 2018 according to SRatingsIntel. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by Leerink Swann on Tuesday, April 24. The firm earned “Outperform” rating on Tuesday, April 24 by Wedbush. The company was initiated on Thursday, February 1 by Roth Capital. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, March 14. The firm has “Buy” rating by Roth Capital given on Tuesday, April 24. SunTrust maintained it with “Buy” rating and $2000 target in Monday, April 23 report. The rating was initiated by Jefferies on Wednesday, January 24 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 14.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart